• Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

  • Aug 22 2024
  • Duración: 8 m
  • Podcast

Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles